Not Signed In -
Abdominal Pain |
Pain, Abdominal |
Clinical Trial: Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes
This study is currently recruiting patients.
Verified by Dartmouth-Hitchcock Medical Center August 2005
|
Purpose
The overall purpose of this project is to improve nurse skills regarding NP assessment, treatment and referral practices through implementation of an evidence-based algorithm and to improve selected patient outcomes as a result of algorithm use.
| Condition | Intervention | Phase |
|---|---|---|
| Pain | Drug: Neurontin | Phase I Phase II |
MedlinePlus related topics: Pain
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Further Study Details:
Primary Outcomes: To implement an evidence based screening assessment treatment and referral guideline for hematology/oncology patients with NP receiving care.
Secondary Outcomes: To pilot test an NP Guideline evaluating patient outcomes and patient perceptions of assessment/treatment
Expected Total Enrollment: 50
Secondary Outcomes: To pilot test an NP Guideline evaluating patient outcomes and patient perceptions of assessment/treatment
Expected Total Enrollment: 50
Study start: August 2005; Expected completion: August 2006
Last follow-up: August 2006; Data entry closure: August 2006
Neuropathic pain (NP) is defined as pain that arised from injury, disease or dysfunction of the central or peripheral nervous system. For the patient focused phase of the project NP treatment will be guided via the Peripheral Neuropathy Treatment Algorithmn. Patients will receive algorithm-specific treatment for 12 weeks.
Eligibility
Ages Eligible for Study: 18 Years - 90 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Cancer patients experiencing NP pain from a variety of causes
- NP VAS score equal to or > 4 with 12 week estimated duration
- KPS 60% or greater
- Age greater than 18
Exclusion Criteria:
- Patients undergoing anticancer or invasive pain procedures specifically intended to palliate NP are ineligible
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00130130
Linda S. Kingman 603-650-8939 Linda.S.Kingman@Hitchcock.ORG
Ellen Lavoie-Smith, ARNP
Ellen Lavoie-Smith, ARNP
New Hampshire
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States; Recruiting
Linda S Kingman 603-650-8939 Linda.S.Kingman@Hitchcock.ORG
Ellen Lavoie-Smith, ARNP
Ellen Lavoie-Smith, ARNP, Principal Investigator
Ellen Lavoie-Smith, ARNP
Ellen Lavoie-Smith, ARNP, Principal Investigator
Study chairs or principal investigators
Ellen Lavoie-Smith, ARNP, Principal Investigator, Dartmouth-Hitchcock Medical Center
More Information
Study ID Numbers: D 0403; ONS
Last Updated: August 12, 2005
Record first received: August 12, 2005
ClinicalTrials.gov Identifier: NCT00130130
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 12, 2005
Record first received: August 12, 2005
ClinicalTrials.gov Identifier: NCT00130130
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-08-23
email this page
print this page
bookmark this page
feedback on this page
